HUTCHMED (China) Limited

NasdaqGS:HCM Stock Report

Market Cap: US$1.9b

HUTCHMED (China) Management

Management criteria checks 4/4

HUTCHMED (China)'s CEO is Johnny Cheng, appointed in Jul 2008, has a tenure of 15.5 years. total yearly compensation is $1.16M, comprised of 32.6% salary and 67.4% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth $3.86M. The average tenure of the management team and the board of directors is 4 years and 3 years respectively.

Key information

Johnny Cheng

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage32.62%
CEO tenure18yrs
CEO ownership0.2%
Management average tenure4yrs
Board average tenure3yrs

Recent management updates

Recent updates

Seeking Alpha • Jul 19

Hutchmed: Bullish On Their Commercial Prospects And Pipeline Catalysts

Summary Hutchmed basically combines a growing oncology franchise with late-stage immunology assets and an early ATTC pipeline. Their Fruzaqla international rollout and improving China execution could also help increase their recurring revenues. Similarly, Sovleplenib, Fanregratinib, and SAFFRON give HCM several options to further derisk its broader pipeline. HCM also has a highly liquid balance sheet and doesn’t appear excessively valued. So, I rate HCM a viable speculative “Buy” at these levels. Read the full article on Seeking Alpha
Seeking Alpha • Jan 30

Despite A Promising Future For Hutchmed, We Have Concerns About Development Of The Share Price (Rating Downgrade)

Summary Despite a 32% drop in share price, HCM's oncology treatments show potential for growth, with expected revenue increases driving earnings and share price up. HCM's sale of a 45% stake in Shanghai Hutchison Pharmaceuticals for $608 million will fund internal product development, enhancing its market position. The current share price of $13.56 suggests an attractive valuation with a FWD P/E of 18.1 and an EV/Sales of 2.44. However, concerns over poor performance of the share prices of Li family-controlled companies led us to downgrade HCM from Buy to Hold. Read the full article on Seeking Alpha
Seeking Alpha • Aug 09

Hutchmed Growing Sales By 64% In H1 2024

Summary Share price up nearly 20% since our previous Buy call. Approval of the colon cancer drug FRUZAQLA by the U.S. FDA was a game-changer to their growth in sales. We expect continued growth in sales of oncology products from the approval of FRUZAQLA in the E.U. and Japan. Read the full article on Seeking Alpha
Seeking Alpha • Mar 20

Hutchmed Is Turning Profitable

Summary Hutchmed China is a biopharmaceutical company with a market capitalization of $3 billion. HCM's total revenue doubled to $838 million in 2023, driven by sales of the cancer drug FRUZAQLA. The company delivered a profit of $100.8 million in 2023 and has a strong cash position of over $880 million. FDA approval at the end of last year, and hopefully similar approvals from the EU and Japan will be a gamechanger for HCM. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Johnny Cheng's remuneration changed compared to HUTCHMED (China)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$1mUS$378k

US$457m

Sep 30 2025n/an/a

US$462m

Jun 30 2025n/an/a

US$467m

Mar 31 2025n/an/a

US$252m

Dec 31 2024US$1mUS$368k

US$38m

Sep 30 2024n/an/a

-US$2m

Jun 30 2024n/an/a

-US$42m

Mar 31 2024n/an/a

US$29m

Dec 31 2023US$962kUS$338k

US$101m

Sep 30 2023n/an/a

US$36m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$195m

Dec 31 2022US$2mUS$329k

-US$361m

Sep 30 2022n/an/a

-US$308m

Jun 30 2022n/an/a

-US$255m

Mar 31 2022n/an/a

-US$235m

Dec 31 2021US$2mUS$318k

-US$195m

Sep 30 2021n/an/a

-US$187m

Jun 30 2021n/an/a

-US$178m

Mar 31 2021n/an/a

-US$151m

Dec 31 2020US$789kUS$310k

-US$126m

Sep 30 2020n/an/a

-US$117m

Jun 30 2020n/an/a

-US$110m

Mar 31 2020n/an/a

-US$102m

Dec 31 2019US$770kUS$298k

-US$106m

Compensation vs Market: Johnny's total compensation ($USD1.16M) is below average for companies of similar size in the US market ($USD5.20M).

Compensation vs Earnings: Johnny's compensation has been consistent with company performance over the past year.

CEO

Johnny Cheng (59 yo)

18yrs
Tenure
US$1,158,008
Compensation

Mr. Chig Fung Cheng, BEc, CA, also known as Johnny, has been Chief Financial Officer of HUTCHMED (China) Limited (formerly known as Hutchison China MediTech Limited) since July 2008 and serves as its Actin...

Leadership Team

NamePositionTenureCompensationOwnership
Chig Fung Cheng
Acting CEO18yrsUS$1.16m0.20%
$ 3.9m
Wei-Guo Su
CEO, Chief Scientific Officer & Executive Director (Leave of Absence)14.5yrsUS$1.75m0.55%
$ 10.5m
Yiling Cui
Executive VP & Head of Operations2.2yrsno datano data
Xinhui Hu
Executive Vice President & Chief Technical Officerless than a yearno datano data
David Ng
Head of Investor Relations & Capital Strategiesno datano datano data
Charles George Rupert Nixon
Group General Counsel11.2yrsno data0.041%
$ 778.4k
Kin Hung Lee
Senior Vice President of Corporate Management & Communications3.5yrsno datano data
Selina Zhang
Senior Vice President of Global Human Resources4.5yrsno datano data
Qingmei Wang
Executive Vice President of Business Development & Strategic Alliancesno datano datano data
Thomas Fu
Senior Vice President of Global Quality5.3yrsno datano data
George Yuan
Executive VP & Head of Commercial of China2.5yrsno datano data
Guangxiu Dai
Executive VPless than a yearno datano data
4.0yrs
Average Tenure
57.5yo
Average Age

Experienced Management: HCM's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chig Fung Cheng
Acting CEO15.5yrsUS$1.16m0.20%
$ 3.9m
Wei-Guo Su
CEO, Chief Scientific Officer & Executive Director (Leave of Absence)9.3yrsUS$1.75m0.55%
$ 10.5m
Edith Shih
Company Secretary & Non-Executive Director20.5yrsno data0.14%
$ 2.7m
Dan Eldar
Non-Executive Chairman9.9yrsUS$130.00k0.018%
$ 333.1k
Ling Yang
Non-Executive Director3yrsno datano data
Renu Bhatia
Lead Independent Non-executive Director2.2yrsUS$105.16k0.0019%
$ 35.4k
Chaohong Hu
Independent Non-Executive Director1.7yrsUS$98.97kno data
Tak Wai Wong
Independent Non-Executive Director1.3yrsUS$83.06kno data
Shao Tan
Independent Non-Executive Directorless than a yearUS$17.95kno data
3.0yrs
Average Tenure
67yo
Average Age

Experienced Board: HCM's board of directors are considered experienced (3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/26 04:26
End of Day Share Price 2026/07/24 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HUTCHMED (China) Limited is covered by 53 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
John NewmanCanaccord Genuity
Adam McCarterCavendish